Entries by ginealach
Two Pharma Giants Link Up With Amphista on Protein Degradation Projects
FDANews – View full story
Article requires subscription to view full text
Multi-billion dollar vote of confidence in UK protein specialist
The Pharma Letter – View full story
Dundee’s Amphista strikes collaboration deals that could be worth billions
The Herald Scotland – View full story
Amphista Therapeutics signs with pharma on drug development projects
Drug Discovery World – View full story
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on […]
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista and Merck will collaborate to leverage Amphista’s proprietary Eclipsys™ TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million*) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to €893.5 million ($1.0 billion*) in total payments […]
